Endo at buy by Jefferies

Endo Pharmaceuticals Holdings Inc. was given a buy rating by Jefferies & Co., Inc. analyst David Windley on weak stock due to pro-forma earnings per share of $0.41, three cents below the analyst's estimate and two cents below consensus. The miss was attributed in part to lower sales of Lidoderm and Frova. Endo's management reaffirmed 2006 guidance. Shares of the Chadds Ford, Pa., pharmaceutical company were down 41 cents, or 1.26%, at $32.19 on volume of 2,244,783 shares versus the three-month running average of 1,576,400 shares. (Nasdaq: ENDP)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.